Previous 10 | Next 10 |
VBI Vaccines press release (NASDAQ:VBIV): FY GAAP EPS of $0.27 beats by $0.54. Revenue of $0.63M (-40.6% Y/Y) misses by $0.17M. As of December 31, 2021 cash, cash equivalents of $121.7M compared with $119.1 million in cash, cash equivalents, and short-term investments as of December...
Prophylactic Hepatitis B (HBV): FDA approval of PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] received in November 2021 PreHevbrio added to ACIP list of recommended adult HBV vaccines in February 2022 U.S. commercial launch of PreHevbrio expected at the end of...
QualTek Names New Independent Board Appointees to its Board of Directors PR Newswire BLUE BELL, Pa. , March 7, 2022 /PRNewswire/ -- QualTek Services Inc. ("QualTek" or the "Company") (NASDAQ: QTEK), a leading turnkey provider of infrastructure services to the...
VBI Vaccines (NASDAQ:VBIV) is trading ~3% higher in the premarket Friday after the commercial stage vaccine maker announced that an expert panel of the European Medicines Agency (EMA) issued a positive opinion on its 3-antigen hepatitis B vaccine. EMA’s Committee for Medicina...
- Following positive CHMP recommendation, final EMA regulatory decision expected in coming months - European Union (EU) brand name to be PreHevbri™ - If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U. VBI Vaccin...
Cambridge, Massachusetts-based vaccine maker VBI Vaccines (NASDAQ:VBIV) announced on Wednesday that an expert panel of the U.S. Centers for Disease Control and Prevention (CDC) approved its Hepatitis B Vaccine, PreHevbrio. VBI Vaccines (VBIV) is currently trading ~6% higher in the p...
- PreHevbrio™ is the only approved 3-antigen hepatitis B vaccine for adults in the U.S. - Vaccine availability is expected to begin later in Q1 2022 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that David E. Anderson, Ph.D, VBI’s Chief Scientific Officer, will present an overview of VBI-1901, the Com...
- A second, two-part Phase 2a/2b study will assess the safety and efficacy of VBI-2601 (BRII-179) as an add-on therapy to standard-of-care treatment in chronic hepatitis B patients - Partner, Brii Biosciences, recently initiated dosing in the newly announced trial, expected to enrol...
Jefferies has assumed coverage of VBI Vaccines (VBIV +0.2%) with a buy rating on the company's "versatile" vaccine technology platform. The firm has a $6 price target on shares (~171% upside based on yesterday's close). Analyst Roger Song says that VBI's platform can provide several large mar...
News, Short Squeeze, Breakout and More Instantly...
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, wa...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s ca...
PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) anno...